Pharma Sample Clauses

Pharma. A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company's primary focus is on its lead product, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma submitted a New Drug Application (NDA) to the FDA in May 2009 and received a Complete Response Letter in March 2010 that outlined several issues that would need to be addressed prior to FDA approval of APF530. The Company is in the process of preparing a resubmission to address the issues outlined in the Complete Response Letter.
Sample 1
AutoNDA by SimpleDocs
Pharma wHEALTH, organized under the laws of the Grand Duchy of Luxembourg as a mutual investment fund (fond commun de placement) (the "Fund"), has retained the Management Company to manage the Fund's assets and appoint such advisors in so doing, and the Management Company desires to engage the Advisor in rendering such services to the Fund.
Sample 1
Pharma. In the event that the products of oral solid dosage form of AND-9 are launched eventually, within ten years after the launch, Shijiazhuang No. 4 Pharma shall pay a sales commission to Zhengzhou University at a rate of 2% of sales revenue for every year after the product launch. The Agreement and the transactions contemplated thereunder do not constitute a notifiable transaction for the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) nor a connected transaction under Chapter 14A of the Listing Rules. UPDATE ON PRODUCT DEVELOPMENT The Board of the Company is also pleased to announce that the Group has obtained the approval for production and registration for Ambroxol Hydrochloride and Sodium Chloride Injection (100ml) in upright polypropylene infusion soft bag from the CFDA. Ambroxol Hydrochloride is mainly used for treatment of respiratory diseases. It promotes mucus clearance and eases cough, and is under previous type 6 chemical drug. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company. By order of the Board Chow Xxxx Xxxxx Company Secretary Hong Kong, 5 March 2018
Sample 1
Pharma. The 2012 special 301 watch report of the US Trade of Representatives cites US industry concern over “the lack of transparency, fairness, and predictability of the PHARMAC pricing and reimbursement regime, as well as the negative access of the overall climate for innovative medicines in NZ” US Negotiating objectives listed in the “fast track” (Trade Priorities Act) xxxx introduced into Congress in Jan 2014 include “the elimination of government measures such as price controls and reference pricing which deny full access for US products” TPPA WILL PROVIDE PHARMACEUTICAL INDUSTRY EXTRA PRIVILEGES
Sample 1
Pharma. Global MENA LTD accepts no liability for any disruption or non-availability of the Website.
Sample 1
Pharma. Global MENA LTD reserves the right to alter, suspend or discontinue any part (or the whole of) the Website including, but not limited to, any products and/or services available. These terms and conditions shall continue to apply to any modified version of the Website unless it is expressly stated otherwise. Limitation of liability
Sample 1
Pharma. If the Property Developer obtains the Land Parcel at the Public Tendering and upon the receipt of the Compensation by Xxxxxxxxxxxx Xx.0 Xxxxxx, Xxxxxxxxxxxx Xx.0 Pharma shall pay the Compensation to the Property Developer. If the Property Developer is unable to obtain the Land Parcel at the Public Tendering, Shijiazhuang No.4 Pharma shall refund the Fixed Income and all other payments made by the Property Developer (without interest) to the Property Developer within 7 working days from the Public Tendering. Shijiazhuang No.4 Pharma shall then be entitled to retain the Compensation received under the Land Repurchase Agreement. If the Property Developer does not participate in the Public Tendering of the Land Parcel, Shijiazhuang No.4 Pharma shall have the right to retain the Fixed Income. Save for the Fixed Income, Shijiazhuang No.4 Pharma shall not participate in the sharing of income or profits from the Project, nor shall it be responsible for the operational losses arising from the Project. The Property Developer shall be responsible for all the development works of the Project, including but not limited to project development and construction, operational management and sales and marketing. The Property Developer shall be responsible for all the funding and investments into the Project. Upon obtaining the Land Parcel, the Property Developer shall also be solely responsible for the development and operations of the Project. As all of the applicable percentage ratios calculated in accordance with the Listing Rules in respect of the disposal of the Land Parcel are less than 5%, the disposal does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.
Sample 1
AutoNDA by SimpleDocs

Related to Pharma

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Cardiff Capital Region has secured a deal worth £1.2 billion. Over its lifetime, local partners expect the City Deal to deliver up to 25,000 new jobs and leverage an additional £4 billion of private sector investment.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • University Any notice may be served upon the University by delivering it, in writing, to the University at the address set forth on the last page of this Agreement, by depositing it in a United States Postal Service deposit box with the postage fully prepaid and with the notice addressed to the University at the aforementioned address, or by sending a facsimile of it to the University facsimile number set forth on the last page of this Agreement.

  • Licensee Licensee represents and warrants that:

  • Generelt A. Apple Inc. (“Apple”) giver hermed licenstager licens til at bruge Apples software samt tredjeparters software, dokumentation, grænseflader, indhold, skrifter og evt. data, som følger med denne licens, uanset om de forefindes som ROM (Read Only Memory) eller på andet medie (under et kaldet “Apple- software”) i henhold til betingelserne i denne licensaftale. Apple og/eller Apples licensgivere bevarer ejendomsretten til selve Apple-softwaren og forbeholder sig alle de rettigheder, som ikke udtrykkeligt er givet til licenstager.

  • Transnet (i) For legal notices: …………………………………………………… …………………………………………………… …………………………………………………… Fax No. ………… Attention: Group Legal Department

  • S.A 59:1-1 et seq.), the New Jersey Contractual Liability Act (N.J.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Licensor any Person from whom a Grantor obtains the right to use any Intellectual Property. Lien: any Person’s interest in Property securing an obligation owed to, or a claim by, such Person, whether such interest is based on common law, statute or contract, including liens, security interests, pledges, hypothecations, statutory trusts, reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting Property. Lien Waiver: an agreement, in form and substance satisfactory to Collateral Agent, by which (a) for any material Collateral located on leased premises, the lessor waives or subordinates any Lien it may have on the Collateral, and agrees to permit Collateral Agent to enter upon the premises and remove the Collateral or to use the premises to store or dispose of the Collateral; (b) for any Collateral held by a warehouseman, processor, shipper, customs broker or freight forwarder, such Person waives or subordinates any Lien it may have on the Collateral, agrees to hold any Documents in its possession relating to the Collateral as agent for Collateral Agent, and agrees to deliver the Collateral to Collateral Agent upon request; (c) for any Collateral held by a repairman, mechanic or bailee, such Person acknowledges Collateral Agent’s Lien, waives or subordinates any Lien it may have on the Collateral, and agrees to deliver the Collateral to Collateral Agent upon request; and (d) for any Collateral subject to a Licensor’s Intellectual Property rights, the Licensor grants to Collateral Agent the right, vis-à-vis such Licensor, to enforce Collateral Agent’s Liens with respect to the Collateral, including the right to dispose of it with the benefit of the Intellectual Property, whether or not a default exists under any applicable License.

Time is Money Join Law Insider Premium to draft better contracts faster.